期刊文献+

TPF方案时辰诱导化疗联合同步放化疗治疗局部晚期鼻咽癌的近期疗效观察 被引量:3

Clinical observation of TPF chrono-chemotherapy with concurrent chemoradiation in the treatment of locally advanced nasopharyngeal carcinoma
下载PDF
导出
摘要 目的探讨TPF时辰诱导化疗联合同步放化疗治疗局部晚期鼻咽癌的近期疗效。方法将117例局部晚期鼻咽癌患者采用随机数字表法分为对照组(57例)和观察组(60例),对照组给予DTX 75 mg/m^2静滴1 h d1(DDP前使用);DDP 75 mg/m^2静滴d1;5-Fu 750 mg/(m^2·d)持续静滴d1~d5,21 d为一个周期,共2周期。观察组DTX 75 mg/m^2,静滴,d1。DDP 75 mg/m^2,分5 d完成静滴给药,每天10:00~22:00。5-Fu 750 mg/(m^2·d),d1~d5,持续静滴,每天22:00~10:00。21 d为一个周期,共2个周期。2组化疗后评价有效者行三维适形调强放疗,同期放疗DDP 80 mg/m^2,d1~d3,静滴,21 d为一个周期,共2周期。分别于治疗前后检测2组患者血清巨噬细胞炎性蛋白-3α(MIP-3α)与半胱氨酸蛋白酶抑制剂A(cystatin A)表达水平并进行临床疗效评定。结果观察组患者鼻咽部肿瘤控制和颈部淋巴结控制有效率为94.74%,92.98%,对照组为92.72%,90.90%,差异无统计学意义(P> 0.05);2组患者血清MIP-3α和cystatin A表达水平均显著低于同组治疗前(P<0.05)。观察组生存质量改善情况显著高于对照组,且观察组不良发生率低于对照组(P<0.05)。结论 TPF方案时辰诱导化疗联合同步放化疗治疗局部晚期鼻咽癌患者近期疗效好,且毒副反应较小,患者耐受性好。 Objective To investigate the clinical efficacy and safety of TPF chrono-chemotherapy with concurrent chemoradiation in the Treatment of locally advanced nasopharyngeal carcinoma.Methods117patients with locally advanced nasopharyngeal carcinoma were randomly divided into control group and observ-ation group.Control group was treated with DTX75mg/m2,infusion,d1;DDP75mg/m^2,infusion,d1;and5-Fu750mg/(m^2·d),continuous infusion,d1~d5,for three courses.Observation group was treated with DTX,75mg/m^2,i.v.infusion,d1;DDP,75mg/m^2,bolus infusion from10:00to22:00,d1~d5;and5-Fu750mg/(m^2·d)bolus infusion from22:00to10:00,d1~d5,with21days each cycle.Patients who obtained therapecutic efficacy via induction chemotherapy were provided with intensity-modulated radiotherapy as a concurrent radiotherapy and chemoth-erapy(DDP80mg/m^2,infusion,d1~d3,with21days each cycle and a total of two courses).Acute and late toxicities were graded according to the Common Terminology Criteria for Adverse Events v3.0scoring criteria.Tumor response was evaluated using2000Response Evaluation Criteria in Solid Tumors criteria.Serum macrophage inflammatory protein-3α(MIP-3α)and cystatin A levels were compared in2groups before and after treatment12months were observed.Results After treatment,The efficient rate of nasopharyngeal carcinoma was94.74%and of cervical lymph node was92.98%in observation group.By contrast,the efficient rate of nasopharyngeal carcinoma was92.72%,and of cervical lymph node90.91%in control group respectively.Results showed no significant difference in the complete response efficient rate of both nasopharyngeal carcinoma and cervical lymph node with two groups(P>0.05).The serum levels of MIP-3αand cystatin A in two groups were significantly lower than those before(P<0.05).The improvement of quality of life in the observation group was better than that in the control group(P<0.05).There was statistical significance in the incidence of ADR between2groups(P<0.05).The vomit rate was29.82%in observation group,which was less than the data was50.91%in control group(P<0.05).Conclusions TPF chrono-chemotherapy with concurrent chemoradiation in the treatment of locally advanced nasopharyngeal carcinoma has a great short-term effects and less side effects,which is an effective,tolerable and safe comprehensive treatment scheme.
作者 黄军 蒙光化 罗再琴 金风 赵明丹 Huang Jun;Meng Guanghua;Luo Zaiqin(The Qiannan Hospital of Traditional Chinese Medicine,Duyun,Guizhou 558000)
出处 《基层医学论坛》 2019年第1期15-18,共4页 The Medical Forum
关键词 局部晚期鼻咽癌 时辰诱导化疗 同步放化疗 巨噬细胞炎性蛋白-3α(MIP-3α) 半胱氨酸蛋白酶抑制剂A(Cystatin A) Nasopharyngeal carcinoma Chrono-chemotherapy Concurrent chemoradiation Macrophage inflammatory protein-3α(MIP-3α) Cystatin A
  • 相关文献

参考文献9

二级参考文献147

  • 1吴金通,彭俊英,吴陈宾,丁纪涛.TPF方案诱导化疗对局部晚期鼻咽癌临床疗效的影响[J].实用癌症杂志,2014,29(2):143-145. 被引量:8
  • 2金风,欧阳金陵,董红敏,吴伟莉,陈海霞,何志惠.鼻咽癌DDP+5-FU/CF方案时辰化疗的临床前瞻性随机研究[J].中国肿瘤临床,2004,31(19):1123-1125. 被引量:25
  • 3田野,蔡清淟,岑信棠.局部晚期鼻咽癌同期放化疗的疗效分析[J].中华肿瘤杂志,2005,27(7):429-431. 被引量:16
  • 4王雅平,华鲁纯,张延龄.生物钟基因与肿瘤[J].国际外科学杂志,2006,33(4):279-283. 被引量:6
  • 5乐凡,叶胜龙.昼夜节律钟基因与肿瘤[J].中国肿瘤生物治疗杂志,2007,14(1):83-86. 被引量:8
  • 6AI-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase Ⅲ randomized Intergroup study 0099 [J]. J Clin Oncol, 1998,16(4) : 1310-1317.
  • 7Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study [J]. J Clin Oncol, 2004,22(13):2643-2653.
  • 8Ogawa T, Terada A, Hyodo I, et al. A Phase Ⅰ study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head and neck [J]. Gan To Kagaku Ryoho, 2005,32 (7) :977-981.
  • 9Chan AT, Ma BB, Lo YM, et al. Phase Ⅱ study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA [J]. J Clin Oncol, 2004,22 (15) : 3053-3060.
  • 10Baujat B, Bourhis J, Chan AT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients [J]. Int J Radiat Oncol Biol Phys, 2006,64:47-56.

共引文献83

同被引文献29

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部